- Home
- RNXT
RNXT
RenovoRx Inc.
as 03-27-2025 4:00pm EST
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | SAN JOSE |
| Market Cap: | 34.0M | IPO Year: | 2021 |
| Target Price: | $6.00 | AVG Volume (30 days): | 78.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.49 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.77 - $1.69 | Next Earning Date: | 05-09-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | 91.76% | Revenue Growth (next year): | N/A |
Latest RenovoRx Inc. News
RNXT Breaking Stock News: Dive into RNXT Ticker-Specific Updates for Smart Investing
Business Wire
a day ago
RenovoRx Pre-Clinical Results Supporting TAMP™ as a Targeted Locoregional Drug Delivery Platform to Receive Award at SIR 2025 Annual Scientific Meeting
Business Wire
7 days ago
RenovoRx CEO to Provide Strategic Update During Fireside Chat on Thursday, April 3rd at 12:00 p.m. ET
Business Wire
8 days ago
RenovoRx Announces Abstract Presentation at the Society of Surgical Oncology (SSO) 2025
Business Wire
a month ago
RenovoRx Advances Commercialization of RenovoCath® with Several New Purchase Orders, Including Customer Reorders
Business Wire
a month ago
RenovoRx Highlights Promising Pre-Clinical Data Abstract: TAMP™ Therapy Platform Offers Potential to Improve Localized and Targeted Drug Delivery
Business Wire
a month ago
RenovoRx Announces Closing of $12.1 Million Underwritten Public Offering of Common Stock
GuruFocus.com
2 months ago
RenovoRx Prices $12.1 Million Public Offering; Shares Decline Post-Announcement
Business Wire
2 months ago
RenovoRx Announces Pricing of $12.1 Million Underwritten Public Offering of Common Stock
Compare RNXT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RNXT RenovoRx Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.